The Southwest Oncology Group analyzed outcome with cytotoxic chemotherapy for previously untreated acute myeloblastic leukemia (AML) from 1982 through 1986. Results with acute promyelocytic leukemia (APL) prompted comparison with patients from 1986 through 1991 and analysis of factors contributing t o APL results. Patient and disease characteristics and treatment outcome were compared for all evaluable patients, with more detailed analysis of factors affecting APL treatment outcome. From 1982 through 1986, median survival and disease-free survival in 45 APL patients were 106 months and greater than 105 months, respectively, versus 6 and 14 months for 417 other AML patients. Such differences were not seen from 1986 through 1991. In the 141 APL patients from 1982 through 1991, after adjusting for significant patient and disease characteristics, higher daunomycin (DNR) doses during induction were significantly associated with higher complete remission rates ( P < .0001), longer survival (P < .0001), and longer DFS (P < .0001). Cytosine ORPHOLOGIC and cytochemical determination of lineage commitment and level of maturation, as standardized by the French American British (FAB) working group, remains the principal approach to subclassification of acute myeloblastic leukemia (AML)."4 One morphologic subtype of AML, acute promyelocytic leukemia (APL) (FAB M3), corresponds essentially to a morphogenotype, with near 1:l correspondence with t(l5; 17) and chimeric fusion of the PML gene on chromosome 15 with the RARa gene on chromosome 17."8 Although initial reports of APL emphasized poor outcome with cytotoxic chemotherapy, with a high frequency of early hemorrhagic deaths caused by coagulation abnormalitie~,~.~ subsequent chemotherapy studies have shown survival for APL similar or slightly superior to other AML variants.""' Recent reports of complete remissions (CRs) in APL with oral all-trans retinoic acid (ATRA) have generated tremendous interest because of the apparent molecular mechanism of action through the aberrant chimeric product of the t(15; 17) translocation, the cellular effect through maturation of malignant cells, and the apparent efficacy, safety, and ease of admini~tration.'~ It should be noted that these remissions have not been sustained with continued ATRA therapy alone,20~21 and international studies are now in progress to evaluate varying combinations of ATRA and chemotherapy for treating APL.
The Southwest Oncology Group analyzed outcome with cytotoxic chemotherapy for previously untreated acute myeloblastic leukemia (AML) from 1982 through 1986. Results with acute promyelocytic leukemia (APL) prompted comparison with patients from 1986 through 1991 and analysis of factors contributing t o APL results. Patient and disease characteristics and treatment outcome were compared for all evaluable patients, with more detailed analysis of factors affecting APL treatment outcome. From 1982 through 1986, median survival and disease-free survival in 45 APL patients were 106 months and greater than 105 months, respectively, versus 6 and 14 months for 417 other AML patients. Such differences were not seen from 1986 through 1991. In the 141 APL patients from 1982 through 1991, after adjusting for significant patient and disease characteristics, higher daunomycin (DNR) doses during induction were significantly associated with higher complete remission rates ( P < .0001), longer survival (P < .0001), and longer DFS (P < .0001). Cytosine ORPHOLOGIC and cytochemical determination of lineage commitment and level of maturation, as standardized by the French American British (FAB) working group, remains the principal approach to subclassification of acute myeloblastic leukemia (AML)."4 One morphologic subtype of AML, acute promyelocytic leukemia (APL) (FAB M3), corresponds essentially to a morphogenotype, with near 1:l correspondence with t(l5; 17) and chimeric fusion of the PML gene on chromosome 15 with the RARa gene on chromosome 17."8 Although initial reports of APL emphasized poor outcome with cytotoxic chemotherapy, with a high frequency of early hemorrhagic deaths caused by coagulation abnormalitie~,~.~ subsequent chemotherapy studies have shown survival for APL similar or slightly superior to other AML variants.""' Recent reports of complete remissions (CRs) in APL with oral all-trans retinoic acid (ATRA) have generated tremendous interest because of the apparent molecular mechanism of action through the aberrant chimeric product of the t(15; 17) translocation, the cellular effect through maturation of malignant cells, and the apparent efficacy, safety, and ease of admini~tration.'~ It should be noted that these remissions have not been sustained with continued ATRA therapy alone,20~21 and international studies are now in progress to evaluate varying combinations of ATRA and chemotherapy for treating APL.
To assess the Southwest Oncology Group (SWOG) experience with cytotoxic chemotherapy of AML, we compared treatment outcome parameters with morphologic analysis for all patients with previously untreated AML registered on SWOG protocols from 1982 through 1986. Initial results for APL prompted further analysis of outcome of all previously untreated AML patients from 1982 through 1991, with detailed analysis of factors contributing to treatment outcome in MI,.
MATERIALS AND METHODS

M
Patients. This study was based on patients who participated in 5 SWOG trials for previously untreated AML (Appendix). Initially arabinoside (Ara-C) induction dose, the inclusion of other chemotherapy agents in induction, postremission therapy (consolidation, maintenance, or bone marrow transplantation) other than DNR, APL subtype, and patient age did not appear t o significantly affect outcome of APL, except for a significant detrimental effect of high-dose Ara-C in consolidation (P = .0042). Morphologic AML subtypes other than APL did not affect outcome. We conclude that high-dose DNR selectively increases survival in APL. This good survival is important for evaluation of combined all-trans retinoic acid (ATRA)/chemotherapy protocols and for planning future combinations of chemotherapy and ATRA. These results illustrate the need t o individualize chemotherapy for subtypes of AML. Therapeutic response of APL is independent of age. Except for APL, morphologic subclassification of AML contributed little prognostic information. 0 1995 b y The American Society of Hematology.
results were analyzed from studies 8124,8522;' and 8561, including most patients with previously untreated AML registered on SWOG protocols between 1982 and 1986 (seven patients were enrolled on study 8600 in 1986). Treatment outcomes for these protocols were similar after adjustment for age, and similar to concurrent therapeutic protocols in the The same patient population has been patients from 1982 to 1991 were the subject of a meeting summary published previo~sly?~ Eligibility criteria for the five AML trials were generally similar, although they differed with respect to age criteria. Study 8124 was open to patieds 15 years or older with no upper age limit. Studies 8522 and 8561, which were intended for elderly patients, were limited to those 65 years of age or older. Specific lower age limits were not defined for studies 8600 and 8706, however, the actual minimum ages of patients on these two adult AML trials were 15 and 18, respectively. Study 8600 was initially open to patients 65 years of age or older on a pilot study basis because of concerns about toxicity; only six such patients entered the trial, which was then limited to patients less than 65 years old. Study 8706, a study involving bone marrow transplantation (BMT), was limited to patients under age 55.
Morphologic analysis. Diagnosis of leukemia in all protocols was based on an absolute BM infiltrate of 50% or more blasts, or an absolute infiltrate of greater than 30% blasts with demonstration of progressive disease. AML was distinguished from acute lymphoblastic leukemia (ALL) by cytochemical positivity for myeloperoxidase or Sudan black B (SBB) andor nonspecific esterase (NSE), with a myeloid pattern of staining for SBB or NSE. Initial analysis was performed at primary institutions, after which Romanowskystained and unstained bone marrow aspirates were submitted to a central repository (University of Utah, Salt Lake City, UT from 1982 through 1989; St Jude Children's Research Hospital, Memphis, TN from 1989 through 1991) for SBB and alpha naphthyl butyrate (ANB) staining using standard method^.^^^^' Central morphologic review was performed by a panel. Cases were diagnosed as AML and subclassified using published FAB criteria as modified by SWOG.'~3~26." Each case was analyzed by two reviewers. If concordant, their diagnosis was adopted; disagreements were resolved at the central repository. Cytogenetics analyses were unavailable on older cases. Immunophenotyping was unavailable on older cases and cytochemical stains were limited to SBB and ANB, limiting recognition of acute megakaryoblastic leukemia and poorly differentiated AML.4" Therapy. A summary of the treatment regimens for each study is provided in the Appendix. All five studies permitted at least one reinduction attempt for patients who failed to achieve CR with the first induction course, and all provided postremission therapy that included daunomycin (DNR) and cytosine arabinoside (Ara-C) for nontransplant patients.
Definitions of response. In all protocols, CR was defined as BM with morphologically normal trilineage hematopoiesis and less than 5% myeloblasts (expressed as a percentage of all nucleated marrow cells), hemoglobin (Hb) greater than 11 g/dL in the peripheral blood (PB) with no red blood cell transfusion for 2 weeks, granulocytes 1 to 9 x 103/pL (1 to 9 X 109/L) with no blast forms, platelets greater than 1 X IOs/pL (1 X IO"&), and no physical evidence of persistent leukemia. Unlike more recent studies, CR was not required to have a documented duration of at least 28 days. Relapse was defined as greater than 10% blasts in BM, or extramedullary recurrence of leukemic blasts.
Statistical analysis. All data for patients included in this study were collected with quality control review according to standard SWOG procedures. Analyses examined the effects of characteristics of patients (age, sex, race), disease (FAB classification, marrow blast and promyelocyte percentages. white blood cell [WBC] count, peripheral blast and promyelocyte percentages and counts, Hb, and platelet count), planned induction treatment (DNR dose, Ara-C dose, presence of other agents), and postremission therapy (consolidation chemotherapy, BMT, maintenance chemotherapy) on outcome (CR rate, survival, and disease-free survival [DFS]). Survival was measured from date of registration on treatment study until death from any cause, with observations censored for patients last known alive. This definition was modified for analyses of the effects of postremission therapy, for which survival was measured from the date CR was established. DFS was measured for all analyses from the date of CR until relapse or death from any cause, whichever occurred first, with censorship at the last date of contact for patients last known alive. CR rates were analyzed using the multivariate logistic regression model.z9 Distributions of survival and DFS were estimated by the method of Kaplan and Meier?' Effects of patient, disease, and treatment factors on survival and DFS were examined using the proportional hazards regression model of Quantitative factors were treated as continuous variables in regression analysis, but grouped when necessary for descriptive tables or figures. Statistical significance of associations is represented by two-tailed P values. In regression analyses, doses of DNR and Ara-C were represented as total planned doses over a single course, eg, 70 mg/m' X 3 was represented as 210 mg/mz. The total planned doses are summarized by study and patient age in the Appendix. An indicator variable was used to indicate the presence or absence of agents in addition to DNR and Ara-C. Analyses of outcomes in relation to treatment characteristics were based on planned treatment rather than treatment actually received, to avoid the inherent bias if patients' prognoses influence the amount of treatment delivered. Analyses of the effects of postremission treatment were limited to patients who were registered for such therapy on protocol and, like the analyses of induction therapy, were based on planned regimens. This approach was taken because data regarding plans for treatment off protocol were not collected for these studies and to avoid the bias mentioned above.
RESULTS
A total of 1,540 patients were registered (see Appendix). Of these, 1,341 (87%) had central pathology review, with the diagnosis of AML confirmed for 1,282 (96%). The remaining 59 cases included 38 diagnoses of ALL, 13 of myelodysplastic syndrome, and 8 other diagnoses. Among the confirmed AML cases, 141 (11%) were classified as M3. The distribution of other subtypes was M1, 19%; M2,40%; M4, 14%; M5, 8%; M6, 3%; M7, 1%; MO, 1%; and other AML, 3%.
Comparison of M 3 and non-kt3. Initial analyses suggested that M3 patients had exceptionally favorable results compared with the other FAB subtypes on the 1982 through 1986 studies (8124, 8522, and 8561), but not on the 1986 through 1991 studies (8600 and 8706). In the 1982 through 1986 studies, the CR rate was 71% for M3 patients and 54% for non-M3 patients ( Table l) . M3 patients tended to be younger; the apparent difference in CR rates was not statistically significant after adjusting for age (P = .48). However the marked superiorities of survival and DFS rates of M3 patients in the 1982 through 1986 studies were highly significant (age-adjusted P < .OOOl; Table 1 , Fig 1) . In contrast, M3 patients did not have superior results compared with non-M3 in the 1986 through 1991 studies; in age-adjusted analyses, the CR rate of M3 patients (47%) was actually somewhat lower than that of non-M3 patients (55%) ( P = .054), there was no significant difference in survival ( P = .76), and DFS of M3 patients was marginally significantly better than non-M3 (P = .064) ( Table 1 , Fig 2) . These analyses strongly suggested that this difference between the earlier and later studies was caused by a change in the outcomes of M3 patients, not of non-M3 patients; compared with M3 patients in the 1986 through 1991 studies, the earlier M3
patients had a significantly better CR rate ( P = .0063), survival ( P = .0015), and DFS ( P = .OOOl). The results for M3 patients on the 1982 through 1986 studies have been remarkable: only 21 of 45 M3 patients died within 3 years after study entry; one additional patient died at 8 years, 10 months; and the remaining 23 patients remain alive after more than 7 years ( Fig 1) ; most deaths occurred within the first 3 months of study entry (33% mortality), with 17% mortality in the first month. The only M3 patient in this period to relapse after 3 years received the attenuated DNR dosage given patients over 50 years on protocol 8124, relapsed at 7 years with M3 morphology and t(15; 17), and died with persistent disease 17 months after relapse. In none of these analyses was there significant heterogeneity of CR rate, survival, or DFS among FAB categories other than M3 (results not shown). Factors influencing M 3 treatment outcome. Further analyses were restricted to the 141 M3 patients in an effort to assess whether differences in treatment regimens might explain differences in outcome. Characteristics of the M3 patients are summarized in Table 2 . Multivariate analyses were conducted to examine effects of planned treatment regimen among M3 patients, with adjustment for significant factors. Of the 141 M3 patients, 77 (57%) achieved CR. 3 summarizes results of logistic regression analyses of CR had marginally significant associations with CR rate: race, rates. Four factors were significantly associated with CR rate marrow blast percentage, WBC count, peripheral blast perin the univariate analyses: induction DNR dose, presence of centage, absolute peripheral blast plus promyelocyte count, induction agents in addition to DNR and Ara-C, percentage and platelet count. Several of these factors are correlated of blasts plus promyelocytes among peripheral leukocytes, with each other; for example, all of the patients whose inducand absolute peripheral blast count. Several other factors tion regimens had DNR at 210 mg/m' were on study 8124, .58
Overall survival and DFS were analyzed using proportional hazards regression models; coefficient < 0 indicates that hazard function decreases (prognosis improves) with increasing value of covariate.
Abbreviations: Coeff, coefficient; M. male; F, female. which included agents in addition to DNR and Ara-C, whereas 88 of the 94 patients on regimens with DNR at 135 mg/m2 were on study 8600, which included no additional agents. Consequently, multivariate analysis identified only four significantly favorable prognostic factors for achieving C R greater DNR dose ( P = .0003), lower absolute peripheral blast plus promyelocyte count ( P = .0033), race other than white ( P = .017), and higher platelet count (P = .023). After accounting for these factors, there was no significant association of the CR rate with Ara-C dose ( P = .92) or the inclusion of other agents ( P = .34).
Further analyses were performed to investigate induction failures. As shown in Table 4 , 54 (38%) of the 141 M3 patients achieved CR with just one induction course. The CR rate after one course increased significantly with increasing induction DNR dose (two-tailed P = .0002 based on logistic regression analysis with adjustment for absolute blast and promyelocyte count and platelet count; race was not significantly related to CR rate after one course [P = .26]). In particular, 24 of 42 (57%) of patients on DNR doses of 180 to 210 mg/m2 achieved CR after one course, compared with 30 of 99 (30%) on 40 to 135 mg/mz. Corresponding to this increasing CR rate with increasing DNR dose was a decreasing death rate: the proportions of patients who failed to achieve CR with one course and who then died before a second course could be given were 6 of 43 (14%) on DNR doses of 180 to 210 mg/m' and 30 of 98 (31 %) on 40 to 135 mg/m' ( P = .057). The majority of these deaths (33 of 36) were caused by disseminated intravascular coagulation (DIC)/hemorrhage and/or infection (Table 5) , and most (28 of 36) occurred within 21 days after study entry.
In studies 8124,8522, and 8561, DNR began on day 1 of induction therapy, whereas in 8600 and 8706 it began on day 5 or 7 (see Appendix). All 35 patients with DNR doses of 210 mg/m' were in study 8124, and 88 of the 94 patients with DNR at 135 mg/m2 were on study 8600. This suggests that the lower CR rate after one course among patients on regimens with DNR at 135 mg/m2 might be caused by the later start of DNR on study 8600, rather than the lower dose. This possibility was supported by the fact that five (83%) of the six patients who received DNR at 135 mg/m2 on study 8124 achieved CR compared with 42 (48%) of 88 patients who received the same dose on study 8600. However, the later start of DNR on study 8600 cannot account for the entire apparent effect of DNR dose because only eight (9%) of the 88 patients on study 8600 died on or before their planned DNR start days. Moreover, among the 127 patients who survived more than 7 days, ie, until after the latest planned start of DNR, the CR rate increased significantly with increasing DNR dose ( P = .W11 with adjustment for race, absolute blast plus promyelocyte count, and platelet count). Among the 34 patients who received a second induction course, 23 (68%) achieved CR (Table 4) . It is interesting that 17 (68%) of the 25 patients who received a second course with DNR at 135 mg/m' achieved CR. However, it is not possible to determine whether this relatively high CR rate (compared with 30% after the first course with 135 mgl m' ) is caused by a cumulative dose effect or by selection of patients in better health and/or with less aggressive disease.
Survival of M3 patients by induction DNR dose and age is shown in Fig 3A. Several factors were related to survival in univariate proportional hazards regression analyses (Table  3) , and multivariate analysis showed that survival increased significantly with increasing DNR dose ( P < .0001), decreasing WBC count ( P < .0001), and decreasing peripheral promyelocyte percentage ( P = .027). Survival was not significantly related to h a -C induction dose (P = .30) or the presence of other agents ( P = .38). Similarly DFS rate ( Fig  3B) increased significantly with increasing DNR dose ( P = .OO01), decreasing WBC count (P = .0003), and decreasing total peripheral blast and promyelocyte count ( P = .0034), but was not significantly related to Ara-C induction dose ( P = .078 for a negative effect) or the presence of other agents ( P = .28) ( Table 3 ). The absence of relapse after CR was notable in patients receiving higher dose DNR induction. Of 30 patients entering CR with 180 to 210 mg/m' DNR induction, only 3 relapsed, 3 died in CR, and 21 remain alive in remission. By contrast, among 47 patients entering CR after induction with 135 mg/m' DNR, 32 relapsed, 4 died in CR.
and only 11 remain alive in remission ( P < . OOO1 for comparison of DFS).
Additional analyses were performed to assess whether differences in post-remission therapy might explain the apparent association of DNR dose during induction with survival and DFS. Fourteen of the 77 M3 patients who achieved CR received no protocol postremission therapy (7 because of induction toxicity or other medical reasons, 6 because of refusal, and 1 because of protocol error). Of the remaining 63 patients, 58 received postremission chemotherapy (21 on 8124, 22 on 8600 high-dose Ara-C plus DNR, and 15 on 8600 or 8706 standard dose Ara-C plus DNR), and 5 received allogeneic BMT as postremission therapy on study 8124. Twenty-three consolidation patients were on studies with postconsolidation therapy, for which 19 were registered; one of the two patients who received consolidation therapy on study 8706 went on to allogeneic BMT on study, and 18 of the 2 1 patients who received consolidation on 8 124 received protocol postconsolidation therapy (1 3 maintenance and intensification, five intensification only). Altogether, six M3 patients received allogeneic BMT on studies 8124 or 8706, which represents 38% of the 16 potential candidates for allogeneic or autologous BMT on study (8124, 13 patients less than 50 years old with CR and suitable donor; 8706, 3 patients with CR). The other 10 potential candidates did not receive BMT because of medical reasons (4 patients), refusal ( 3 , or preference for consolidation because of delay in scheduling BMT (1) .
Analyses of postremission therapy were limited to the 63 patients who were registered for such treatment on study, and took the following into account: DNR and Ara-C doses and presence of other agents for patients on consolidation, and allogeneic BMT on study 8124. These characteristics of postremission therapy did not significantly influence survival ( P = .078), but did appear to influence DFS rate somewhat (P = ,015). The latter effect was largely caused by poorer prognosis in relation to increasing Ara-C dose during consolidation ( P = .0042) ( Table 6 ). Although the effect for all patients is striking (right columns) (1 8 of 22 high-dose Ara- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From C relapsed v 11 of 36 standard-dose Ara-C), this is clearly distorted by the unequal distribution of high-dose DNR patients to standard-dose Ara-C. The apparent independent negative effect of high-dose Ara-C is best shown in the 135 DNR columns; of 39 patients who received 135 mg/m'/ course induction DNR, 17 received standard-and 22 highdose Ara-C consolidation. Ten patients receiving standarddose Ara-C relapsed and 7 are alive in CR; 18 patients receiving high-dose Ara-C relapsed, 2 died in CR. and only 2 remain alive in CR (P = .026 for DFS). A marginal negative effect of Ara-C dose was also seen for survival ( P = .061). There was no significant effect of DNR dose during consolidation on either survival ( P = .45) or DFS (P = .68). After adjusting for the effects of postremission therapy, the effect of induction DNR dose remained statistically significant for survival (P = .0033) and DFS (P = .0023).
Of the 58 patients registered for protocol consolidation treatment, 19 were subsequently registered for postconsolidation therapy on study. One of these patients was nonrandomly assigned to receive allogeneic BMT as postconsolidation therapy on study 8706. The remaining 18 were randomized between intensification only (5 patients) and intensification plus maintenance (13) on study 8124. Because only 4 of these 18 patients have relapsed or died, it is not possible to assess reliably whether postconsolidation therapy influenced outcomes.
In univariate analyses of outcomes among the M3 patients (Table 3) , age was not a significant prognostic factor for CR ( P = .33) or DFS ( P = 0.22) rates, and was only marginally significant for overall survival ( P = .035). After adjusting for DNR induction dose and the significant patient and disease characteristics, there was no significant effect of age on outcomes in M3 patients whether age was treated as a dichotomous variable less than 50 versus 2 5 0 years ( P = .28 for CR, 0.96 for survival, 0.52 for DFS) or as a continuous variable ( P = .36 for CR, 0.46 for survival, 0.90 for DFS) ( Table 3, Fig 3) . Among the 98 patients on studies with the lower induction doses of DNR (5135 mg/m'/course), the less than-50 and z50-years age groups had nearly identical CR rates of 47% and 48%, respectively (Table 4) . A higher CR rate of 71% was seen among the 41 M3 patients less than 50 years old on regimens with higher doses of DNR. Only one patient more than 50 years old was on a regimen with DNR dose over 135, a 53 year old on study 8706 who achieved CR and was last known alive without report of relapse at 36 months. Figure 3 shows patterns similar to CR: little difference by age among patients receiving lower doses of DNR, and a pronounced effect of higher-dose DNR among patients less than 50 years old. With the available data it is not possible to assess whether the positive effect of high DNR dose in M3 patients less than 50 years old would be the same for patients more than 50 years old.
Hypergranular versus microgranular APL. Among the 141 M3 patients, 24 (17%) were microgranular APL (M3v). Characteristics for classic hypergranular M3 (M3h) versus M3v patients are summarized in Table 2 . The percentage of nonwhite patients was higher in the M3v group (33% v 12%) ( P = .014). Patients with M3v had higher blast percentages in marrow ( P = .OOO2) and PB ( P < .OOOl), and higher WBC (P < .OOOl) and absolute peripheral blast counts ( P < .OOOl). Response rates were similar for the two groups:
12 of 24 CR (50%) for M3v and 64 of 116 (56%) for M3h ( P = .66 in univariate analysis; P = -90 in multivariate analysis). There was no significant interaction between the effects on CR rate of induction DNR dose and M3 subtype ( P = .90). There were no significant differences between M3v and M3h patients with respect to survival (P = .085 in univariate analysis, P = .l7 in multivariate analysis) or DFS ( P = .74 in univariate analysis, P = .41 in multivariate analysis). There were no significant interactions between the effects of DNR dose and M3 subtype for survival ( P = .14) or DFS (P = .16).
Planned versus delivered dose of therapy. Although all analyses were based on planned, as opposed to delivered, therapy, we analyzed delivered dose of DNR at each step of therapy in patients receiving high dose DNR, to insure that planned doses of DNR could be delivered. During each step of therapy the vast majority of high-dose DNR patients received 100% ? 10% DNR therapy (induction course 1,88% of patients; induction course 2, 75%; consolidation course 1, 79%; consolidation course 2, 59%; and intensification course 1, 79%), and few received drastically reduced (less than 75%) DNR dosage at any step of therapy (induction course 1, 5%, 1 of 2 because of protocol error; induction course 2,25%, 2 of 3 because of protocol error; consolidation course 1,20%; consolidation course 2, 24%; and intensification course 1, 7%).
DISCUSSION
APL was initially described as an AML variant with particularly poor prognosis, largely because of associated coagulation abnormalities, often precipitated by administration of cytotoxic ~hemotherapy.~,' More recent reports cite better survival with chemotherapy in APL, sometimes exceeding other subtypes of AML.L@'2.'7.'8. 32 We report here exceptional outcome (61% survival at 9 years, no relapses after 3 years) for patients with M3 AML treated with high-dose DNR in induction (210 mg/m' per course) and consolidation (420 mg/m2). Similar to other chemotherapy reports, most deaths in our M3 patients occurred during the first 3 months of treatment, with 17% mortality during the first month. Prior" and subsequent SWOG trials and reports by ~t h e r s '~* ' ' .~' -~~ with lower-dose anthracycline regimens, have failed to show this marked survival advantage. Multivariate analysis of CR rate, survival, and DFS among our M3 patients provides strong evidence that outcome of APL relates to the DNR dose used. Highly significant associations were seen between induction DNR dose and each of these endpoints, both initially and after adjusting for patient and disease characteristics with prognostic significance. We failed to show, but could not disprove, an effect of combined induction/ consolidation DNR dose on survival and DFS. Studies by other^'^"^ using induction anthracycline doses similar to with induction DNR of 300 mg/m2/induction course, but no further anthracycline therapy, had a CR rate of 53% with median survival of 5 months and median CR duration of 10 months. Thomas et al,35 using a variety of regimens with up to DNR 210 mg/m*/induction course, but generally lowerdose DNR in consolidation, had an overall CR rate of 6 4 % with median CR duration of 18 months. A similar pattern has been found in studies in which other anthracyclines have been used with higher doses in induction and lower dose or no anthracycline in con~olidation.~~*~' This review and our data suggest that a combination of prolonged delivery and/ or total DNR dose may be more important than induction dose alone in curing APL. However, because of our protocol designs, our analysis failed to either prove or disprove this suggestion because DNR induction dose and consolidation dose were partially linked in our protocols (of the two largest protocols in this analysis, protocol-8124 patients less than 50 years old received an induction DNR dose of 210 mg/m' and maximum inductionkonsolidation dose of 630 mg/m2, v protocol 8600 with induction DNR dose of 135 mg/m2 and total DNR of only 270 mg/m' [an induction DNR ratio for these two protocols of 1.6:1, but a total DNR ratio of 2.3: l]).
Outcome of M3 did not relate significantly to Ara-C induction dose (standard or high), or to addition of other drugs to the induction regimen. Other postremission treatment (consolidation, maintenance, BMT) did not appear to affect outcome significantly in a positive way. There was a significant negative effect of postremission high-dose Ara-C, principally caused by an increased incidence of relapse in patients who received this consolidation regimen; we have no explanation for this finding. Because most deaths occurred within the first 3 months of institution of therapy, with very few relapses after CR, BMT in first remission does not appear to be a useful addition to this chemotherapy regimen. APL subtype (M3v v M3h) did not significantly affect outcome and did not interact with DNR dose. Because our results were not obtained from a single randomized trial, other confounding factors in our analysis cannot be entirely excluded; none were identified despite a detailed search.
Although others have noted improved treatment results in APL with addition of anthracyclines to AML therapy, we know of no biologic reason for sensitivity of APL to high-dose DNR.3' Nevertheless, this sensitivity illustrates a set of important observations in A M L . The excellent results with SWOG 8124 were selective for APL; other identifiable patient groups showed no benefit. Highdose Ara-C had no beneficial effect, and indeed, a significant deleterious effect in M3 in this analysis. M3 is essentially a morphogenotype; there are similar reports of differential chemosensitivity with other agents among genotypes of Ah4L [excellent survival in AML with inv( 16) or t(8;21) with high-dose Ara-C, excellent survival in de novo t(9; 11) Ah4L with chemotherapy including epipodophylotoxins, and poor survival with similar chemotherapy for AML as a wholeM (and this report), and the beneficial effect of high-dose Ara-C in AML with inv(l6) or t(8;21) is not found in APL4' (and this report). In the future, tailoring chemotherapy to specific biologic subgroups of AML may give superior results to current generic treatment protocols. The relatively good survival of M3 in elderly patients in these studies, approximating survival in younger patients receiving similar therapy, indicates specific AML subgroups also have a major influence on treatment outcome in the elderly. Poor overall outcome in AML in the elderly may relate largely to poor prognostic AML subgroups.
Analyses of these studies were conducted based on planned, as opposed to delivered, chemotherapy. This is the appropriate basis for analyzing clinical study results and for planning subsequent trials for three reasons. (l) Analyses based on delivered doses are inherently subject to bias based on patient outcome. For example, a patient dying on the second day of therapy will receive reduced therapy; a patient with an intercurrent infection ultimately leading to death may receive attenuated therapy during the infection. It is unlikely in either case the reduced therapy contributed to ultimate outcome. (2) Analyses based on planned doses provide a realistic basis for predicting outcome of subsequent trials. If planned dosage in subsequent trials is based on delivered dose in prior trials, the delivered dose in the subsequent trials will likely be less than the delivered dose in the prior trials. (3) Analyses bases on planned dose correspond to clinical reality; in practice treatment plans are implemented without prescient knowledge of whether full doses will in actuality be delivered. By contrast, the appropriate role for analysis of delivered dosage of drugs is to assess whether planned doses in a protocol were too toxic to be delivered. If most patients received most of the regimen, then it can serve as the basis for future trials; if most patients received drastically attenuated therapy because of toxicity or refusal, then the regimen must obviously be modified. In the current case, the vast majority of APL patients on high-dose DNR regimens received acceptable doses of this therapy, with excellent results, indicating these regimens are suitable for design of future therapeutic trials.
Given excellent CR rates for APL treated with ATRA (with few early deaths but relapse with continued ATRA therapy a l~n e ) , '~-~' and flat long-term survival of APL treated with high-dose DNR (with frequent early deaths but very few relapses after CR), combination of the two regimens is attractive. Randomized studies of combined ATRNchernotherapy versus chemotherapy alone for APL are underway in both Europe and the United Because of possible different survival curves for ATRNchemotherapy combinations (potential for decreased early deaths) versus optimal chemotherapy (early deaths but few relapses), final analysis of these Abbreviation: POMP, vincristine 2 mg/m' intravenously day 1, prednisone 100 mg/mz orally daily x5, 6 -mercaptopurine 500 mg/m2 intravenously days 1 through 5, methotrexate 7.5 mg/mz intravenously days 1 through 5.
* DNR and Ara-C dose schedule and route of administration, by total dose per course in milligrams per square meter, are as follows: DNR at 210 mglrn', 70 mg/m2 intravenously on days 1 through 3; DNR at 135 mglrn', 45 mglrn' intravenously on days 1 through 3; DNR at 90 mg/ m' , 30 mg/mZ intravenously on days 1 through 3; Ara-C at 1,800 mg/rnz, 100 mg/m2 intravenously every 12 hours on days 1 through 9 for a total of 18 times; Ara-C at 1,400 mg/m2 induction, 100 mglm' intravenously every 12 hours on days 1 through 7 for a total of 14 times; Ara-C at 1,400 mg/m2 consolidation, 100 mg/m' intravenously push every 12 hours on days 1 through 7 until December 1982, then 200 mg/m2 intravenously on days 1 through 7; Ara-C at 700 mglm', 100 mg/m2 intravenously on days 1 through 7; Ara-C at 400 mg/m2, 20 mg/m' every 6 hours 20 times on days 1 through 5.
t Induction, consolidation, intensification, and maintenance regimens all included the following other agents: vincristine, prednisone, and 6-thioguanine. Consolidation course 1 also included Cytoxan until May 1983. * Patients less than 50 years old and with an HLA-identical family donor available were nonrandomly assigned to allogeneic BMT; all others were assigned to consolidation chemotherapy.
§ Postconsolidation patients were randomly assigned to Intensification Only or Intensification and Maintenance.
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